Dermira (Dermira) Net Margin % : -499.62% (As of Sep. 2019)

View and export this data going back to 2014. Start your Free Trial

What is Dermira Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Dermira's Net Income for the three months ended in Sep. 2019 was $-57.62 Mil. Dermira's Revenue for the three months ended in Sep. 2019 was $11.53 Mil. Therefore, Dermira's net margin for the quarter that ended in Sep. 2019 was -499.62%.

The historical rank and industry rank for Dermira's Net Margin % or its related term are showing as below:

DERM's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -162.58
* Ranked among companies with meaningful Net Margin % only.

Dermira Net Margin % Historical Data

The historical data trend for Dermira's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermira Net Margin % Chart

Dermira Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Net Margin %

Get a 7-Day Free Trial

-436.64

-1,073.96

-394.44

-6,678.29

-523.25

Dermira Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Net Margin %	Get a 7-Day Free Trial															-9,280.89	-3,201.52	-2,644.05	-26.95	-499.62

Competitive Comparison of Dermira's Net Margin %

For the Biotechnology subindustry, Dermira's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dermira's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dermira's Net Margin % distribution charts can be found below:

* The bar in red indicates where Dermira's Net Margin % falls into.

Dermira Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Dermira's Net Margin for the fiscal year that ended in Dec. 2018 is calculated as

Net Margin	=	Net Income (A: Dec. 2018 )	/	Revenue (A: Dec. 2018 )
	=	-221.54	/	42.339
	=	-523.25 %

Dermira's Net Margin for the quarter that ended in Sep. 2019 is calculated as

Net Margin	=	Net Income (Q: Sep. 2019 )	/	Revenue (Q: Sep. 2019 )
	=	-57.621	/	11.533
	=	-499.62 %

Dermira (NAS:DERM) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Dermira Net Margin % Related Terms

Thank you for viewing the detailed overview of Dermira's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Dermira (Dermira) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermira Inc (NAS:DERM) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Middlefield Road, Suite 150, Menlo Park, CA, USA, 94025

Website

http://www.dermira.com

Dermira Inc is a biopharmaceutical company focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States.The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.

Executives

Halley E Gilbert	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
William R Ringo	director
Fred B Craves	director	750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
David E Cohen	director	3160 PORTER DRIVE, PALO ALTO CA 94304
Thomas G Wiggans	director, officer: CEO & Chairman of the Board
Jason Raleigh Nunn	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
Andrew Guggenhime	officer: CFO	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Lori Lyons-williams	officer: Chief Commercial Officer	C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Kathleen Sebelius	director	C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Eugene A Bauer	director, officer: Chief Medical Officer	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Lilly Eli & Co	10 percent owner	LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Mark Mcdade	director	C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Matthew K Fust	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Canaan Partners Viii Llc	director	285 RIVERSIDE AVE, STE 250, WESTPORT CT 06880
Canaan Viii Lp	director	2765 SAND HILL RD, MENLO PARK CA 94025